يرجى استخدام متصفح الكمبيوتر الشخصي للوصول إلى التسجيل - تداول السعودية
حسنًا
Reported Saturday, Assembly Biosciences Presents Phase 1a And Preclinical Data For ABI-5366 And ABI-1179 Herpes Candidates At STI & HIV 2025 And International Herpesvirus Workshop
Assembly Biosciences, Inc. +0.30%
Assembly Biosciences, Inc. ASMB | 33.60 | +0.30% |
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –
– Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted –
– Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 –
